BMJ1d
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical ...
BMJ3d
Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014
Objectives To examine trends in the incidence of rheumatoid arthritis (RA) from 2005 to 2014 overall and by serological status as compared with 1995–2004 and 1985–1994. Methods We evaluated RA ...
BMJ3d
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
Background Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several randomised clinical trials ...
BMJ3d
Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment
Objectives Fatigue is a frequent symptom in rheumatoid arthritis (RA) and has high impact on quality of life. We explored associations between disease activity and fatigue in patients with early RA ...
BMJ4d
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine
Professor D L Scott, King's College Hospital, East Dulwich Grove, Dulwich, London SE22 8PT, UKleigh.joyce{at}kcl.ac.uk OBJECTIVE Recent studies have demonstrated the short term efficacy of leflunomide ...
BMJ4d
Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine
Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands Professor R Landewé, Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical ...
BMJ4d
Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis
Correspondence to Prof Nicola Dalbeth, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1, New Zealand; n.dalbeth{at}auckland.ac.nz Objectives To ...
BMJ8d
Psoriatic arthritis: epidemiology, clinical features, course, and outcome
1 University of Toronto, Toronto Western Research Institute, Psoriatic Arthritis Program, University Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, ...
BMJ9d
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
Aims Treating to low disease activity is routine in rheumatoid arthritis, but no comparable goal has been defined for systemic lupus erythematosus (SLE). We sought to define and validate a Lupus Low ...
BMJ10d
Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
Objective This observational cohort study investigated the impact of biological (b) disease-modifying antirheumatic drugs (DMARDs) on the outcomes of serious infections (SIs) in patients with ...
BMJ10d
Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial
7 National Referral Centre for Rare Systemic Auto-immune Diseases, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France Objectives To evaluate the effect of adding a 10-week treatment of ...
BMJ10d
Baseline predictors of different types of treatment success in rheumatoid arthritis
Objective To perform a comprehensive analysis on predictors of achieving disease activity outcomes by change, response and state measures. Methods We used data from three rheumatoid arthritis (RA) ...